Lead Product(s) : Taplucainium
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Nocion Therapeutics Announces First Patient Dosed in ASPIRE Phase 2b Chronic Cough Study
Details : NOC-110 (taplucainium) is a proprietary molecule in the novel class of charged sodium channel blockers, being investigated for the treatment of chronic cough.
Brand Name : NOC-110
Molecule Type : Small molecule
Upfront Cash : Not Applicable
November 18, 2024
Lead Product(s) : Taplucainium
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
LOOKING FOR A SUPPLIER?